Barbara, Juanita and Emma have all been diagnosed with HR+/HER2- metastatic breast cancer and have been prescribed a CDK4/6 inhibitor. Can you help us select the optimal CDK4/6 inhibitor for each of our three patients?
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest
Developed by EPG Health for Medthority. This content has been developed independently of the sponsor Eli Lilly, who have had no editorial input into the content. EPG Health received unrestricted educational funding from the sponsor in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.